-
Ebb & Flow Convincing converts At least one bondholder is unhappy with last week's plan to split Theravance Inc. (NASDAQ:THRX) into two publicly traded companies. One company - Theravance Biopharma - will be …
Published on 4/29/2013
-
Ebb & Flow Alleviating lesions Morgenthaler believes it has finally found a good entry point into wound healing via Scioderm LLC's $16 million series A round. The proceeds will fund a therapy to treat chronic wounds…
Published on 4/29/2013
-
Ebb & Flow Legal tracks Wendy Goldstein joined Cooley as a partner in its healthcare and life sciences regulatory practice. She was a partner at Epstein Becker & Green. Genevieve Michaux joined Hunton & Williams as…
Published on 4/22/2013
-
Vertex's vertical leap Money Raised in 2013 Last week, the biotech industry raised $228 million, bringing to $6.9 billion the total raised year-to-date. In 2012, a total of $36.3 billion was raised, including $19.9 …
Published on 4/22/2013
-
Vertex's vertical leap Earnings on deck At least 17 biotechs and pharmas are slated to report earnings this week. Four big biotechs - Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Amgen Inc. (NASDAQ:AMGN), Biogen Idec…
Published on 4/22/2013
-
Vertex's vertical leap EPS watch At least five biotechs and pharmas reported earnings last week. Actelion Ltd. (SIX:ATLN) added more than $230 million to its market value after reporting 1Q13 revenues and EPS that …
Published on 4/22/2013
-
Ebb & Flow Remodeling the model The Thiel Foundation's Breakout Labs program has emerged from its pilot year of awards with modified grant terms intended to create a revolving funding model. The foundation, …
Published on 4/22/2013
-
Ebb & Flow Lucier's long position Life Technologies Corp. (NASDAQ:LIFE) Chairman and CEO Greg Lucier went on a buying spree after taking the helm at predecessor Invitrogen Corp. in 2003. The strategy appears to have…
Published on 4/22/2013
-
Ebb & Flow Regulatory milestones BTG plc (LSE:BTG) was off 12.30p to 344.50p last week after Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Zytiga abiraterone from Johnson & Johnson (NYSE:…
Published on 4/22/2013
-
Ebb & Flow Dutch dance Following the results of Elan Corp. plc's $1 billion Dutch auction share buyback last Thursday, Royalty Pharma hopes remaining Elan shareholders will accept an $11.25 per share takeout bid …
Published on 4/22/2013
-
The audiophiles Inner ear pipeline At least 13 compounds are in development for inner ear disorders, including hearing loss, Meniere's disease, tinnitis and vertigo. The most advanced is neramexane to treat tinnitis…
Published on 4/22/2013
-
Sofinnova Partners and Sofinnova Ventures think scientific advances and unmet need in inner ear disorders are making audiology an investable space, with Auris among the leaders in the race.
Published on 4/22/2013
-
Ebb & Flow Vertex's vertical leap Table: Earnings on deck Figure: Money Raised in 2013 Table: EPS watch Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) leapt $32.73 (62%) to $85.60 on Friday after positive Phase II …
Published on 4/22/2013
-
Ebb & Flow Banker tracks Stuart Smartt joined NXT Capital as a managing director and head of healthcare for the firm's corporate finance group. Smartt was a director of the healthcare group at CIT Group. PE tracks…
Published on 4/15/2013
-
Ebb & Flow The lather over Sarepta Table: Earnings on deck Figure: Money Raised in 2013 Phase II clinical data for drisapersen from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) provided grist for supporters and …
Published on 4/15/2013
-
The lather over Sarepta Money Raised in 2013 Last week, the biotech industry raised $526 million, bringing to $6.6 billion the total raised year-to-date. In 2012, a total of $36.3 billion was raised, including $19.9…
Published on 4/15/2013
-
The lather over Sarepta Earnings on deck At least five biotechs and pharmas are slated to report earnings this week. 1Q13 EPS for Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is expected to decline by 31% despite a 15%…
Published on 4/15/2013
-
Last week's flurry of IPO news, including the largest offering since 2011, suggest biotech companies think an IPO window has been cracked open.
Published on 4/15/2013
-
Ebb & Flow Cydan's orphanage Newco Cydan LLC is entering the rare disease space with the aim of launching five companies over the next four years around assets sourced from academia, not-for-profits and industry …
Published on 4/15/2013
-
Ebb & Flow De-risking money Cleave Bioscience Inc.'s investors allowed New Enterprise Associates to add $10 million last week on the same terms as a 2011 A round because the lion's share of money and de-risking is …
Published on 4/15/2013
-
Ebb & Flow Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient …
Published on 4/15/2013
-
Ebb & Flow PE tracks Healthcare private equity firm Health Evolution Partners promoted David Smith to general partner and head of the firm's portfolio services group from senior operating partner. --Kevin …
Published on 4/8/2013
-
Figure: Money Raised in 2013 Although OriGene Technologies Inc. is profitable, it tapped private investors for $21.3 million in a series C …
Published on 4/8/2013
-
Expanding a profit story Money Raised in 2013 Last week, the biotech industry raised $109 million, bringing to $6.1 billion the total raised year-to-date. In 2012, a total of $36.3 billion was raised, including $19.…
Published on 4/8/2013
-
Ebb & Flow Company builder Several months after Vatera Holdings became Rib-X Pharmaceuticals Inc.'s biggest backer, the firm has now installed a handpicked CEO and new commercial head. The moves suggest any plans …
Published on 4/8/2013